Decreased outer membrane permeability protects mycobacteria from killing by ubiquitin-derived peptides.
Ubiquitin-derived peptides are bactericidal in vitro and contribute to the mycobactericidal activity of the lysosome. To further define interactions of ubiquitin-derived peptides with mycobacteria, we screened for mutants with increased resistance to the bactericidal activity of the synthetic ubiquitin-derived peptide Ub2. The four Ub2-resistant Mycobacterium smegmatis mutants were also resistant to the bactericidal action of other antimicrobial peptides and macrophages. Two mutants were in the mspA gene encoding the main M. smegmatis porin. Using a translocation-deficient MspA point mutant, we showed that susceptibility of M. smegmatis to Ub2 was independent of MspA channel activity. Instead, the M. smegmatis Ub2-resistant mutants shared a common phenotype of decreased cell wall permeability compared with wild-type bacteria. Expression of mspA rendered Mycobacterium tuberculosis CDC1551 more susceptible both to ubiquitin-derived peptides in vitro and to lysosomal killing in macrophages. Finally, biochemical assays designed to assess membrane integrity indicated that Ub2 treatment impairs membrane function of M. smegmatis and M. tuberculosis cells. The M. smegmatis Ub2-resistant mutants were more resistant than wild-type M. smegmatis to this damage. We conclude that Ub2 targets mycobacterial membranes and that reduced membrane permeability provides mycobacteria intrinsic resistance against antimicrobial compounds including bactericidal ubiquitin-derived peptides.
Purdy
Georgiana E
GE
Department of Microbiology and Immunology, Cornell University, College of Veterinary Medicine, Ithaca, NY 14853, USA. purdyg@ohsu.edu
Niederweis
Michael
M
Russell
David G
DG
D000995:Antitubercular Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D002462:Cell Membrane / Q000502:physiology*; D004252:DNA Mutational Analysis; D024881:Drug Resistance, Bacterial; D008264:Macrophages / Q000382:microbiology; D050296:Microbial Viability; D020125:Mutation, Missense; D020102:Mycobacterium smegmatis / Q000187:drug effects*; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics; D010455:Peptides / Q000493:pharmacokinetics / Q000494:pharmacology*; D010539:Permeability; D018272:Porins / Q000235:genetics; D025801:Ubiquitin / Q000493:pharmacokinetics / Q000494:pharmacology*
D000995:Antitubercular Agents; D010455:Peptides; D018272:Porins; D025801:Ubiquitin; C121838:mspA protein, Mycobacterium smegmatis
J Bacteriol. 2009 Jan;191(2):625-31
19011036
Curr Opin Immunol. 2002 Feb;14(1):96-102
11790538
Microbiology (Reading). 2008 Mar;154(Pt 3):679-692
18310015
Infect Immun. 2000 May;68(5):2671-84
10768959
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6121-6
12724526
Cell. 2004 Dec 17;119(6):753-66
15607973
PLoS Pathog. 2005 Sep;1(1):e2
16201014
J Exp Med. 1992 Apr 1;175(4):1111-22
1552282
Nat Rev Microbiol. 2005 Mar;3(3):238-50
15703760
J Immunol. 2007 Jun 1;178(11):7190-8
17513768
Microbes Infect. 2009 Sep;11(10-11):868-75
19460455
FEMS Microbiol Lett. 1998 Jan 1;158(1):75-81
9453159
Cell Microbiol. 2008 Feb;10(2):529-48
17986264
Mol Microbiol. 2003 Sep;49(5):1167-77
12940978
Mol Microbiol. 1995 Jun;16(5):991-1000
7476195
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6031-6
17389386
J Immunol. 1998 Feb 1;160(3):1290-6
9570546
J Biol Chem. 1997 May 16;272(20):13326-31
9148954
Cell Microbiol. 2006 Feb;8(2):242-56
16441435
Int J Med Microbiol. 2004 Oct;294(4):235-45
15532981
Antimicrob Agents Chemother. 2004 Nov;48(11):4163-70
15504836
Proc Natl Acad Sci U S A. 1997 May 13;94(10):5243-8
9144222
Antimicrob Agents Chemother. 2008 Jul;52(7):2503-11
18458127
Microbiology (Reading). 2004 Apr;150(Pt 4):853-864
15073295
J Exp Med. 1996 Oct 1;184(4):1349-55
8879207
J Immunol. 2004 Mar 1;172(5):3070-7
14978112
J Cell Sci. 1998 Apr;111 ( Pt 7):897-905
9490634
Cell Host Microbe. 2007 Nov 15;2(5):352-64
18005756
Mol Microbiol. 2001 Apr;40(2):451-64
11309127
Science. 1994 Feb 4;263(5147):678-81
8303277
Microbiology (Reading). 2005 Jul;151(Pt 7):2403-2410
16000730
Biochem J. 1999 Dec 15;344 Pt 3:845-9
10585872
Trends Microbiol. 2001 May;9(5):237-41
11336841
Immunity. 2007 Jul;27(1):11-21
17663981
Infect Immun. 2003 Feb;71(2):922-9
12540574
J Leukoc Biol. 2007 Oct;82(4):934-45
17609338
Nature. 2002 Jan 24;415(6870):389-95
11807545
Nature. 2001 Nov 22;414(6862):454-7
11719807
J Biol Chem. 2004 May 14;279(20):21257-65
15001577
Infect Immun. 2005 Jun;73(6):3492-501
15908378
Tuber Lung Dis. 1997;78(5-6):237-46
10209678
Antimicrob Agents Chemother. 2008 Sep;52(9):3127-34
18559650
Mol Microbiol. 2005 Nov;58(3):714-30
16238622